Overview

Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This study is a double-blind placebo-controlled trial evaluating the efficacy of raloxifene in the prevention of bone mineral density loss in patients receiving long term corticosteroids.
Phase:
Phase 4
Details
Lead Sponsor:
Tuen Mun Hospital
Collaborator:
Eli Lilly and Company
Treatments:
Raloxifene Hydrochloride